MetaADEDB 2.0 @ LMMD
Levorphanol
(RWTWIZDKEIWLKQ-IWWMGODWSA-N)
Structure
SMILES
O[C@H]([C@H](C(=O)O)O)C(=O)O.Oc1ccc2c(c1)[C@]13CCCC[C@H]3[C@@H](C2)N(CC1)C
Molecular Formula:
C21H29NO7
Molecular Weight:
407.457
Log P:
0.8957
Hydrogen Bond Acceptor:
8
Hydrogen Bond Donor:
5
TPSA:
138.53
CAS Number(s):
N/A
Synonym(s)
1.
Levorphanol
2.
Levorphan
3.
3-Hydroxy-N-methylmorphinan
4.
L-Dromoran
5.
Levo-Dromoran
6.
Levodroman
7.
Levorphanol Tartrate
8.
3 Hydroxy N methylmorphinan
9.
L Dromoran
10.
Levo Dromoran
11.
LevoDromoran
12.
Tartrate, Levorphanol
External Link(s)
MeSHD007981
PubChem Compound5464027
BindingDB50367919
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1NauseaFAERS: 17US FAERS
2Drug ineffectiveFAERS: 10US FAERS
3Inappropriate schedule of drug administrationFAERS: 10US FAERS
4HeadacheFAERS: 9US FAERS
5PainFAERS: 9US FAERS
6VomitingFAERS: 8US FAERS
7PruritusFAERS: 6US FAERS
8DizzinessFAERS: 5US FAERS
9Therapy cessationFAERS: 4US FAERS
10ErythemaFAERS: 3US FAERS
11Feeling abnormalFAERS: 3US FAERS
12MalaiseFAERS: 3US FAERS
13PalpitationsFAERS: 3US FAERS
14Product dose omissionFAERS: 3US FAERS
15Abdominal PainFAERS: 2US FAERS
16AgitationFAERS: 2US FAERS
17ArthralgiaFAERS: 2US FAERS
18Chest PainFAERS: 2US FAERS
19ConstipationFAERS: 2US FAERS
20Disease ProgressionFAERS: 2US FAERS
21DyspepsiaFAERS: 2US FAERS
22FatigueFAERS: 2US FAERS
23HypersensitivityFAERS: 2US FAERS
24Intentional product use issueFAERS: 2US FAERS
25NervousnessFAERS: 2US FAERS
26Peripheral swellingFAERS: 2US FAERS
27PneumoniaFAERS: 2US FAERS
28Sedation complicationFAERS: 2US FAERS
29SomnolenceFAERS: 2US FAERS
30Unevaluable eventFAERS: 2US FAERS
31Weight decreasedFAERS: 2US FAERS
32Abdominal discomfortFAERS: 1US FAERS
33Accidental overdoseFAERS: 1US FAERS
34AneurysmFAERS: 1US FAERS
35AnxietyFAERS: 1US FAERS
36AstheniaFAERS: 1US FAERS
37Atrial FibrillationFAERS: 1US FAERS
38Blood glucose decreasedFAERS: 1US FAERS
39Blood glucose increasedFAERS: 1US FAERS
40Cerebrovascular accidentFAERS: 1US FAERS
41Cold sweatFAERS: 1US FAERS
42CryingFAERS: 1US FAERS
43Dry skinFAERS: 1US FAERS
44DysuriaFAERS: 1US FAERS
45EpistaxisFAERS: 1US FAERS
46FlatulenceFAERS: 1US FAERS
47Hearing disabilityFAERS: 1US FAERS
48Impaired driving abilityFAERS: 1US FAERS
49IncoherentFAERS: 1US FAERS
50Intentional product misuseFAERS: 1US FAERS
51Joint swellingFAERS: 1US FAERS
52Lip swellingFAERS: 1US FAERS
53Medication overuse headacheFAERS: 1US FAERS
54Mental impairmentFAERS: 1US FAERS
55Mouth swellingFAERS: 1US FAERS
56MyalgiaFAERS: 1US FAERS
57NephrolithiasisFAERS: 1US FAERS
58Pharmaceutical product complaintFAERS: 1US FAERS
59Product substitution issueFAERS: 1US FAERS
60Restless Legs SyndromeFAERS: 1US FAERS
61Serotonin SyndromeFAERS: 1US FAERS
62Therapeutic product effect decreasedFAERS: 1US FAERS
63Throat irritationFAERS: 1US FAERS
64TinnitusFAERS: 1US FAERS
65TremorFAERS: 1US FAERS
66Urinary IncontinenceFAERS: 1US FAERS
67Urinary RetentionFAERS: 1US FAERS
68Visual ImpairmentFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.